1-09-2025, 14:05

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -
Globe Newswire1-09-2025, 14:05
9-08-2025, 02:25

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -
Globe Newswire9-08-2025, 02:25
28-04-2025, 20:23

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -
Globe Newswire28-04-2025, 20:23